AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, âCassavaâ, the âCompanyâ), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development of simufilam, Cassavaâs investigational candidate for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy.
Related Questions
How will Dr. Hulihan's appointment affect the timeline and milestones for simufilam's development?
Will the halfâtime commitment of Dr. Hulihan raise concerns about resource allocation for other programs?
Does the appointment suggest any upcoming clinical trial updates or data releases for simufilam?
Is there any indication that this change will affect the company's cash burn rate or upcoming financing needs?
How might the market react to the leadership change given Dr. Hulihan's background and reputation?
Could this appointment influence analyst coverage or consensus estimates for SAVA stock?
What are the potential shortâterm price movements versus longâterm valuation implications of this news?
What impact could this have on Cassava's partnership or licensing agreements with other biotech firms?
How does this leadership move compare to recent CMO appointments at competing CNSâfocused companies?
Will the increased focus on TSC-related epilepsy expand Cassiope's target market and revenue potential?